Gopal, A. K., Chen, R., Smith, S. E., Ansell, S. M., Rosenblatt, J. D., Savage, K. J., . . . Younes, A. (2015). Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Blood.
Citación estilo ChicagoGopal, Ajay K., et al. "Durable Remissions in a Pivotal Phase 2 Study of Brentuximab Vedotin in Relapsed or Refractory Hodgkin Lymphoma." Blood 2015.
Cita MLAGopal, Ajay K., et al. "Durable Remissions in a Pivotal Phase 2 Study of Brentuximab Vedotin in Relapsed or Refractory Hodgkin Lymphoma." Blood 2015.
Precaución: Estas citas no son 100% exactas.